BERRY GENOMICS(SZ:000710) Zheng Quan Shi Bao Wang·2025-01-09 04:19Core Viewpoint - Berry Genomics has announced the successful delivery and testing of the Vega platform, a desktop long-read sequencing platform developed in collaboration with Pacific Biosciences, aimed at enhancing genetic testing solutions for clinical needs in China and abroad [1][2]. Group 1: Product Development and Features - The Vega platform integrates the capabilities of PacBio's Revio system into a compact, medium-throughput desktop platform, utilizing HiFi technology to ensure data accuracy and turnaround time [1][2]. - The platform is designed to provide comprehensive solutions for various applications, including targeted sequencing, RNA sequencing, and small genome sequencing [1][2]. - The introduction of the Vega platform significantly improves the economic viability and accessibility of HiFi long-read sequencing, enabling more researchers to utilize this technology [2][3]. Group 2: Market Strategy and Clinical Applications - Berry Genomics plans to accelerate the development of customized genetic testing solutions based on the Vega platform to meet the growing clinical demands in both domestic and international markets [2][4]. - The company aims to enhance its market promotion efforts to facilitate the sales of the Vega platform, transitioning its business model from genetic testing services to upstream equipment and reagent sales [4][5]. - The Vega CNDx model is being developed to align with the characteristics of the Chinese population and clinical needs, contributing to the localization of sequencing platforms [5]. Group 3: Collaboration and Industry Position - PacBio's COO highlighted Berry Genomics' critical role in the development of the Vega platform, emphasizing the importance of their early testing and data accumulation from the Sequel II system [4]. - The collaboration is expected to deepen, leveraging Berry Genomics' extensive experience in the Chinese clinical market to tailor the Vega platform to meet local demands [4]. - Berry Genomics is positioning itself in the upstream core equipment market, recognizing sequencing instruments as a key component with high industry barriers [4].